REW 40 Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(NQ: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News
Press releases about
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
AVI BioPharma Announces Update on AVI-5038, Its PPMO Duchenne Muscular Dystrophy Drug Candidate, to Be Presented April 14, 2010 at the American Academy of Neurology Annual Meeting
March 25, 2010
from Marketwired News Releases
Biotech Stock Alert for AVI BioPharma Inc. Issued by Beacon Equity
March 18, 2010
from GlobeNewswire News Releases
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results
March 16, 2010
Financial Results and Corporate Update Conference Call Today at 8:30 a.m. Eastern Time (5:30 a.m. Pacific) Read More
from Marketwired News Releases
AVI BioPharma Announces Fourth Quarter and Full Year 2009 Financial Results and Corporate Update Conference Call
March 09, 2010
from Marketwired News Releases
AVI BioPharma Receives Grants Totaling $500,000 From CureDuchenne and the Foundation to Eradicate Duchenne to Support Continuing Development of Drug Candidates to Treat Duchenne Muscular Dystrophy
February 15, 2010
from Marketwired News Releases
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystrophy
February 05, 2010
from Marketwired News Releases
AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology
February 04, 2010
from Marketwired News Releases
Systemic Treatment With AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy Patients
December 22, 2009
Positive RNA and Protein Signals in First Cohorts Analyzed; Conference Call Scheduled Today at 8:30 AM Eastern Time Read More
from Marketwired News Releases
AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference
November 19, 2009
from Marketwired News Releases
AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
November 18, 2009
from Marketwired News Releases
AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate Highlights
November 09, 2009
AVI-4658 for Duchenne Muscular Dystrophy in Final Cohort and on Track for Interim Data Read More
from Marketwired News Releases
AVI BioPharma Announces Third Quarter 2009 Financial Results Conference Call
November 02, 2009
from Marketwired News Releases
AVI BioPharma Presents Updated Safety Data From Ongoing Systemic Trial of AVI-4658 at 7th Annual Action Duchenne International Conference
October 26, 2009
Data Show PMO Well Tolerated in Penultimate Dose Cohort (10mg/kg) Read More
from Marketwired News Releases
AVI BioPharma to Present Safety Update From Ongoing Systemic Trial of AVI-4658 at 7th Annual Action Duchenne International Conference
October 22, 2009
from Marketwired News Releases
Exon Skipping Drug Prevents Muscle Wasting and Maintains Muscle Function in Severely Affected, Dystrophin Deficient Mice
October 20, 2009
New Publication in Molecular Therapy Outlines Dramatic Effects in Animals Treated With Splice Switching PPMO, Demonstrates Promise for Treatment of Duchenne Muscular Dystrophy Read More
from Marketwired News Releases
Exon Skipping Therapy Shows Promise in Prevention or Delay of Heart Disease Associated With Duchenne Muscular Dystrophy
October 19, 2009
Publication in Cardiovascular Research Demonstrates Ability of PPMO to Prevent Cardiomyopathy in Mouse Model of DMD Read More
from Marketwired News Releases
Beacon Equity Issues Trading Overview for AVI BioPharma Inc.
October 07, 2009
from GlobeNewswire News Releases
AVI BioPharma Receives Expanded Contract From U.S. Department of Defense to Develop Its Drug Candidate for the Treatment of Junin Virus Infection
October 05, 2009
$11.5 Million New Funding Brings Total Award to $45 Million Read More
from Marketwired News Releases
RothmanResearch.com Stock Review for BIDU, MXIM, AVII, PAYX, CTXS and PCBC
October 02, 2009
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by RothmanResearch.com. Read More
from Marketwired News Releases
TheFortuneFinancial.com Free Market Research on CTXS, NUAN, PMTC, CWTR, AVII and WERN
September 21, 2009
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by TheFortuneFinancial.com. Read More
from Marketwired News Releases
AVI BioPharma, Inc. Announces Presentations at Upcoming Investment Conferences
September 15, 2009
from Marketwired News Releases
AVI BioPharma, Inc. Demonstrates Effectiveness of Immune Control via RNA-Based Therapeutics in Hemorrhagic Virus Infections
September 14, 2009
Findings Presented at 49th ICAAC Conference Read More
from Marketwired News Releases
AVI BioPharma Presents Safety Data in Duchenne Muscular Dystrophy at 14th Annual International Congress of the World Muscle Society
September 14, 2009
AVI-4658 Demonstrates Encouraging Human Safety Profile, Targeted Exon Skipping and New Dystrophin Production in Phase 1 Intramuscular Injection Study; Preliminary Data From Ongoing Phase 1b/2 Systemic... Read More
from Marketwired News Releases
AnalystChoice.com Brings You the Best Complimentary Research Report on CAKE, GMCR, ADBE, DISH, AVII and MSCC
September 08, 2009
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by AnalystChoice.com (AC). Read More
from Marketwired News Releases
Market Pulse Breaking News Alert for Wednesday, September 2, 2009: ARYC -- Arrayit Lands Patent for Population Scale Diagnostics in World's Most Populous Country!
September 02, 2009
NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse. Read More
from Marketwired News Releases
AVI BioPharma, Inc. Presenting at Rodman & Renshaw Global Investment Conference
September 02, 2009
from Marketwired News Releases
AVI BioPharma, Inc. to Present Leading PPMO Drug Delivery Technology at Upcoming Scientific Meetings
August 27, 2009
from Marketwired News Releases
AVI BioPharma Phase 1 Proof of Concept and Safety Data for AVI-4658 in Duchenne Muscular Dystrophy Featured in Lancet Neurology
August 25, 2009
AVI-4658 Demonstrates Compelling Proof of Concept and Safety Profile for Pediatric Patients With DMD; Findings Support Progression to Current Systemic Use Trial Read More
from Marketwired News Releases
AVI BioPharma to Present Safety Data in Duchenne Muscular Dystrophy at 14th Annual International Congress of the World Muscle Society
August 25, 2009
AVI-4658 Demonstrates Compelling Safety Profile, Targeted Exon Skipping and New Dystrophin Production in Intramuscular Injection Study; Preliminary Data From Ongoing Systemic Study Also to Be Presented... Read More
from Marketwired News Releases
AVI BioPharma Announces Closing of Public Offering of Common Stock and Warrants
August 25, 2009
from Marketwired News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here